查詢結果分析
相關文獻
頁籤選單縮合
題名 | Management of Chemotherapy-induced Hepatitis B Virus Reactivation= |
---|---|
作者 | Huang, Yi-hsiang; Lin, Han-chieh; Lee, Shou-dong; |
期刊 | Journal of the Chinese Medical Association |
出版日期 | 20120800 |
卷期 | 75:8 2012.08[民101.08] |
頁次 | 頁359-362 |
分類號 | 415.5332 |
語文 | eng |
關鍵詞 | Antiviral treatment; Chemotherapy; Hepatitis B virus; Reactivation; |
英文摘要 | Hepatitis B virus (HBV) reactivation induced by cytotoxic chemotherapy is an important issue in cancer patients. An elevated HBV viral load usually precedes hepatitis flare, and hepatic decompensation and eventual death is not infrequent once viral reactivation is initiated. Reverse seroconversion from hepatitis B surface antigen (HBsAg)-negative to HBsAg-positive would also occur in hepatitis B core antibody (anti-HBc)- positive patients. The risk of HBV reactivation can be attributed to patient viral status and the regimen of chemotherapeutic agents. Chemotherapeutic regimens that contain steroid and rituximab can increase the risk of viral reactivation in lymphoma patients. Consequently, routine HBV marker screening, including HBsAg and anti-HBc, is mandatory prior to chemotherapy for all cancer patients, and prophylactic antiviral treatment is highly recommended for HBsAg-positive cases. However, for patients who are anti-HBc-positive and HBsAg-negative, so-called resolved hepatitis B patients, regular HBV viral load survey during the course of chemotherapy is necessary to early detect HBV reactivation. Currently, the role of antiviral prophylaxis for resolved hepatitis B patients is still unsettled. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。